Unraveling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2
Abstract
The Adaptive COVID Treatment Trial-2 (ACTT-2) found that baricitinib in combination with remdesivir therapy (BCT) sped recovery in hospitalized coronavirus disease 2019 (COVID-19) patients vs remdesivir monotherapy (RMT). We examined how BCT affected progression throughout hospitalization and utilization of intensive respiratory therapies.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 27, 2022
- Source ID
- 10.1093/ofid/ofac219
Entities
People
- Aneesh K. Mehta
- Anuradha Ganesan
- Christina A Rostad
- Constance A Benson
- Corri B Levine
- Daniel A. Sweeney
- Hana M El Sahly
- John H Beigel
- Jonathan Fintzi
- Maria G Frank
- Nikhil Huprikar
- Pablo Tebas
- Pauline K Park
- Richard A Mularski
- Robert L Atmar
- Susan L F Mclellan
- Tyler Bonnett
- Vincent C Marconi
- William R Short
Organizations
- Baylor College of Medicine
- Emory University
- Frederick National Laboratory for Cancer Research
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- Seoul National University Hospital
- Uniformed Services University of the Health Sciences
- United States Department of Defense
- University of California, San Diego
- University of Colorado School of Medicine
- University of Michigan
- University of Pennsylvania
- University of Texas Medical Branch